These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19929210)

  • 1. Pellets for oral administration of low-molecular-weight heparin.
    Scala-Bertola J; Gajdziok J; Rabisková M; Bonneaux F; Lecompte T; Sapin A; Maincent P
    Drug Dev Ind Pharm; 2009 Dec; 35(12):1503-10. PubMed ID: 19929210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granules in the improvement of oral heparin bioavailability.
    Scala-Bertola J; Rabiskova M; Lecompte T; Bonneaux F; Maincent P
    Int J Pharm; 2009 Jun; 374(1-2):12-6. PubMed ID: 19446753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of a microencapsulated low-molecular-weight heparin to rabbits: anti-Xa and anti-IIa profiles.
    Javot L; Sapin A; Scala-Bertola J; Vigneron C; Lecompte T; Maincent P
    Thromb Haemost; 2010 Jun; 103(6):1254-67. PubMed ID: 20390227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system.
    Hoffart V; Lamprecht A; Maincent P; Lecompte T; Vigneron C; Ubrich N
    J Control Release; 2006 Jun; 113(1):38-42. PubMed ID: 16697485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
    Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
    J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies.
    Ito Y; Kusawake T; Prasad YV; Sugioka N; Shibata N; Takada K
    Int J Pharm; 2006 Jul; 317(2):114-9. PubMed ID: 16631328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
    Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
    J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
    Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
    Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system.
    Lanke SS; Gayakwad SG; Strom JG; D'souza MJ
    J Microencapsul; 2009 Sep; 26(6):493-500. PubMed ID: 18846463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability of plasma anti-Xa activities with different lots of enoxaparin.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How and when to monitor a patient treated with low molecular weight heparin.
    Boneu B; de Moerloose P
    Semin Thromb Hemost; 2001 Oct; 27(5):519-22. PubMed ID: 11668422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant effect at the time of epidural catheter removal in patients receiving twice-daily or once-daily low-molecular-weight heparin and continuous epidural analgesia after orthopedic surgery.
    Douketis JD; Kinnon K; Crowther MA
    Thromb Haemost; 2002 Jul; 88(1):37-40. PubMed ID: 12152674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo investigation of low molecular weight heparin-alginate beads for oral administration.
    Iskenderoğlu C; Acartürk F; Erdoğan D; Bardakçi Y
    J Drug Target; 2013 May; 21(4):389-406. PubMed ID: 23350807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.